December 18, 2018 Melinta Therapeutics, Inc. Suite 301 New Haven, Connecticut 06511Melinta Therapeutics, Inc. /New/ • December 19th, 2018 • Pharmaceutical preparations • New York
Melinta Therapeutics, Inc. (the “Borrower”) has requested that Vatera Healthcare Partners LLC (“VHP”) and Vatera Investment Partners LLC (“VIP” and, collectively with VHP, the “Initial Lenders”) provide the Borrower with an up to $135,000,000 senior subordinated convertible loan facility (the “Facility”) on the terms and subject to the conditions set forth in Exhibit A hereto (the “Term Sheet”). Defined terms used but not defined herein shall have the meanings given thereto in the Term Sheet.
